Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


EXPIRED  

Product information

Pegvisomant

EU orphan designation number: EU/3/01/023
Active ingredient: Pegvisomant
Indication: Treatment of acromegaly
Sponsor: Pfizer Limited
Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Somavert on 13/11/2002 with the number EU/1/02/240

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/02/2001 Centralised Orphan - Designation EMEA/OD/035/00 (2001)359 of 14/02/2001
18/10/2001 Centralised Orphan - Transfer of orphan designation EMEA/OD/035/00/T/01 (2001)3103 of 17/10/2001
06/11/2003 Centralised Orphan - Transfer of orphan designation EMEA/OD/035/00/T/02 (2003)4028 of 04/11/2003
15/11/2012 Centralised Orphan - Removal of orphan designation from Community Register